pain score by the use of Numeric Rating Scale (NRS) on arrival to PACU, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"
Opioid-free Anesthesia in Laparoscopic Cholecystectomies
Brief Summary
Intervention / Treatment
-
ketamine-lidocaine-dexmedetomidine (DRUG)In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution.
-
Fentanyl (DRUG)In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
Condition or Disease
- Pain, Postoperative
- Pain, Acute
- Pain, Chronic
- Cholecystectomy
- Ketamine
- Dexmedetomidine
- Lidocaine
- Central Nervous System Depressants
- Analgesia
- Analgesics
- Analgesic Non-narcotic
Phase
Study Design
Study type: | INTERVENTIONAL |
---|---|
Status: | Recruiting |
Study results: | No Results Available |
Age: | 25 Years to 75 Years |
Enrollment: | 70 (ESTIMATED) |
Allocation: | Randomized |
Primary Purpose: | Prevention |
MaskingQUADRUPLE:
|
Clinical Trial Dates
Start date: | Oct 11, 2021 | ACTUAL |
---|---|---|
Primary Completion: | Jun 30, 2023 | ESTIMATED |
Completion Date: | Jun 30, 2023 | ESTIMATED |
Study First Posted: | Oct 22, 2021 | ACTUAL |
Last Updated: | Feb 23, 2023 |
Sponsors / Collaborators
Therefore, in recent years research has focused on the quest for non-opioid-based regimens for perioperative analgesia in the context of multimodal analgesic techniques. These techniques have been shown to possess significant advantages, such as allowing earlier mobilization after surgery, early resumption of enteral feeding and reduced hospital length of stay. In this context, the intraoperative intravenous injection of lidocaine has been reported to improve postoperative pain control, reduce opioid consumption and improve the quality of postoperative functional recovery after general anesthesia. Intraoperative infusions of ketamine (an N-methyl-D-aspartate receptor inhibitor) have also been correlated with reduced pain scores and a decrease in analgesic requirements postoperatively. Lastly, dexmedetomidine is a highly selective alfa-2 adreno-ceptor agonist that provides sedation, analgesia, and sympatholysis. Its perioperative intravenous administration has been associated with a reduction in postoperative pain intensity, analgesic consumption and nausea. There is insufficient data in literature investigating the effect of combinations of these agents intraoperatively. It would be of interest to demonstrate whether the administration of combinations can be used towards the achievement of a completely opioid-free anesthetic regimen. Additionally, it can be hypothesized that the combination of non-opioid drugs with different targets can lead to enhanced postoperative recovery, an improved opioid-sparing effect and a decrease in the development of chronic pain as compared to the administration of opioids. Therefore, the aim of this study will be to investigate the effect of a combination of intravenous infusions of lidocaine-ketamine-dexmedetomidine versus fentanyl on recovery profile and postoperative pain after elective laparoscopic cholecystectomy.
Participant Groups
-
combination of ketamine-lidocaine-dexmedetomidine in one syringe
-
syringe of fentanyl
Eligibility Criteria
Sex: | All |
---|---|
Minimum Age: | 25 |
Maximum Age: | 75 |
Age Groups: | Adult / Older Adult |
Healthy Volunteers: | Yes |
* adult patients
* American Society of Anesthesiologists (ASA) classification I-II
* elective laparoscopic cholecystectomy
Exclusion Criteria:
* body mass index (BMI) \>35 kg/m2
* contraindications to local anesthetic administration or non-steroidal agents administration
* systematic use of analgesic agents preoperatively
* chronic pain syndromes preoperatively
* neurological or psychiatric disease on treatment
* pregnancy
* severe hepatic or renal disease
* history of cardiovascular diseases/ arrhythmias/ conduction abnormalities
* bradycardia(\<55 beats/minute)
* drug or alcohol abuse
* language or communication barriers lack of informed consent
This clinical trial is recruiting
Are you interested in participating in this trial or others? We'd love to help.
Primary Outcomes
-
-
pain score by the use of Numeric Rating Scale (NRS) at discharge from PACU, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"
-
pain score by the use of Numeric Rating Scale (NRS) 3 hours postoperatively, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"
-
pain score by the use of Numeric Rating Scale (NRS) 6 hours postoperatively, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"
-
pain score by the use of Numeric Rating Scale (NRS) 24 hours postoperatively, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"
Secondary Outcomes
-
duration of patient stay at PACU
-
sedation will be assessed with a 5-point sedation scale, where: 1, patient perfectly conscious; 2, patient feels a little drowsy; 3, patient seems to be sleeping but immediately reacts to verbal stimulation; 4, patient seems to be sleeping but slowly reacts to verbal stimulation and 5, patient seems to be sleeping and does not react to verbal stimulation but does react to a stimulus such as shaking or pain
-
sedation will be assessed with a 5-point sedation scale, where: 1, patient perfectly conscious; 2, patient feels a little drowsy; 3, patient seems to be sleeping but immediately reacts to verbal stimulation; 4, patient seems to be sleeping but slowly reacts to verbal stimulation and 5, patient seems to be sleeping and does not react to verbal stimulation but does react to a stimulus such as shaking or pain
-
the sevoflurane vaporizer will be weighed before anesthetic induction and at the end of anesthesia and consequently sevoflurane consumption during anesthesia will be determined
-
the time for the first patient request for analgesia will be noted
-
mg of morphine requested during patient PACU stay
-
patients will be followed for cumulative tramadol consumption for 24 hours postoperatively
-
subjective evaluation of sleep quality by patients, based on a sleep questionnaire (evaluation of sleep duration, number of nocturnal awakenings and marking of sleep quality
-
patients will be questioned regarding the time at which they mobilized after surgery
-
patients will be questioned regarding the time they first felt enteral sounds and the time they had their first flatus after surgery
-
satisfaction from postoperative analgesia on a six-point Likert scale with 1 marked as minimal satisfaction and 6 as maximal satisfaction
-
patients will be questioned regarding the time they had their first fluid intake
-
patients will be questioned regarding the time they had their first solid intake
-
duration of hospital stay after surgery in hours
-
dose of required fentanyl intraoperatively to maintain systolic arterial blood pressure and heart rate within the 20% of baseline value
-
patients will be monitored for side-effects of the administered agents intraoperatively
-
patients will be monitored for side-effects of the administered agents postoperatively
-
occurrence of chronic pain at the site of the operation 1 month after surgery, with the use of the Numeric Rating Scale (NRS), at rest and during movement
-
occurrence of chronic pain at the site of the operation 3 months after surgery, with the use of the Numeric Rating Scale (NRS), at rest and during movement
Other Outcomes
-
time from sevoflurane discontinuation to first patient response (eye opening)
-
time from sevoflurane discontinuation to tracheal extubation
More Details
NCT Number: | NCT05089526 |
---|---|
Other IDs: | lap-chol-opioid free |
Study URL: | https://clinicaltrials.gov/study/NCT05089526 |